These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14505089)

  • 21. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES.
    Kim SJ; Lee C; Lee SY; Kim I; Park JS; Sasagawa T; Ko JJ; Park SE; Oh YK
    Gene Ther; 2003 Aug; 10(15):1268-73. PubMed ID: 12858192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.
    White WI; Wilson SD; Palmer-Hill FJ; Woods RM; Ghim SJ; Hewitt LA; Goldman DM; Burke SJ; Jenson AB; Koenig S; Suzich JA
    J Virol; 1999 Jun; 73(6):4882-9. PubMed ID: 10233949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
    Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
    Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco.
    Lenzi P; Scotti N; Alagna F; Tornesello ML; Pompa A; Vitale A; De Stradis A; Monti L; Grillo S; Buonaguro FM; Maliga P; Cardi T
    Transgenic Res; 2008 Dec; 17(6):1091-102. PubMed ID: 18491213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
    Kawana K; Matsumoto K; Yoshikawa H; Taketani Y; Kawana T; Yoshiike K; Kanda T
    Virology; 1998 Jun; 245(2):353-9. PubMed ID: 9636375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inducible expression of human papillomavirus-16 L1 capsomeres in the plastomes of Nicotiana tabacum: Transplastomic plants develop normal flowers and pollen.
    Latif S; Gottschamel J; Syed T; Younus I; Gull K; Sameeullah M; Batool N; Lössl AG; Mariz F; Müller M; Mirza B; Waheed MT
    Biotechnol Appl Biochem; 2022 Apr; 69(2):596-611. PubMed ID: 33650709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice.
    Li LL; Wang HR; Zhou ZY; Luo J; Xiao XQ; Wang XL; Li JT; Zhou YB; Zeng Y
    Antiviral Res; 2016 Apr; 128():20-7. PubMed ID: 26821205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins.
    Windram OP; Weber B; Jaffer MA; Rybicki EP; Shepherd DN; Varsani A
    Arch Virol; 2008; 153(3):585-9. PubMed ID: 18175039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.
    Baek JO; Seo JW; Kim IH; Kim CH
    Protein Expr Purif; 2011 Feb; 75(2):211-7. PubMed ID: 20716445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco.
    Huang Y; Liang W; Wang Y; Zhou Z; Pan A; Yang X; Huang C; Chen J; Zhang D
    Viral Immunol; 2005; 18(4):668-77. PubMed ID: 16359233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods.
    Matić S; Masenga V; Poli A; Rinaldi R; Milne RG; Vecchiati M; Noris E
    Plant Biotechnol J; 2012 May; 10(4):410-21. PubMed ID: 22260326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
    Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
    Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.
    Leder C; Kleinschmidt JA; Wiethe C; Müller M
    J Virol; 2001 Oct; 75(19):9201-9. PubMed ID: 11533183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
    Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
    Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.